Edrophonium is a cholinesterase inhibitor used to diagnose and evaluate myasthenia gravis. It has also been used as an antidote to curare principles.
- Mechanism
- Curator reviewed
Edrophonium works by prolonging the action acetylcholine, which is found naturally in the body. It does this by inhibiting the action of the enzyme acetylcholinesterase. Acetylcholine stimulates nicotinic and muscarinic receptors. When stimulated, these receptors have a range of effects.
- Primary indication
- For the differential diagnosis of myasthenia gravis and as an adjunct in the evaluation of treatment requirements in this disease.Curator reviewed · 9 structured indications
- Formula / weight
- C10H16NO · 166.2401 g/mol (avg)
- First approval
- Canada, 1999 · United States, 1991
- Also known as
- Edrophonium ion
- Brand names
Resolves to
Clinical / RWD
Structure
InChIKey
VWLHWLSRQJQWRG-UHFFFAOYSA-OSMILESCC[N+](C)(C)C1=CC(O)=CC=C1Targets
What you can answer from here — as of September 23, 2026
2Protein targetsEach mapped to UniProt, with action and pharmacological actionListed above
Which drugs share a target with Edrophonium, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account